The United Nations-backed Medicines Patent Pool announced a potential licensing agreement Friday (May 27) that would allow low- and middle-income countries to manufacture generic versions of injectable pre-exposure prophylaxis (PrEP) for HIV. Cabotegravir is administered monthly or every two months, so wide-spread availability of the drug would go a long way toward reaching the goal of ending the HIV epidemic, MPP Executive Director Charles Gore said. “In particular, it could be a game-changer in prevention. It is critical that it...